论文部分内容阅读
目的研究血管紧张素受体Ⅱ(ATⅡ)的AT1受体阻滞剂伊贝沙坦对2型糖尿病(T2DM)大鼠肾皮质趋化因子fractalkine表达的影响。方法制备T2DM大鼠模型,随机分为正常对照组、糖尿病组及伊贝沙坦治疗组。分别用半定量RT-PCR和免疫组化法检测肾皮质fractalkine mRNA和蛋白表达。结果糖尿病组血清糖基化终产物-肽、尿素氮(BUN)、24h尿总蛋白(24hUPro)、肾皮质fractalkine mRNA和蛋白表达均明显高于对照组;伊贝沙坦治疗组血清BUN、24hUPro、肾皮质fractalkine mRNA和蛋白表达则明显低于糖尿病组。结论伊贝沙坦可能通过抑制肾皮质fractalkine表达发挥其肾保护作用。
Objective To investigate the effect of irbesartan, an AT1 receptor antagonist of angiotensin Ⅱ receptor (AT Ⅱ), on the expression of fractalkine in the renal cortex of type 2 diabetes mellitus (T2DM) rats. Methods T2DM rat model was established and randomly divided into normal control group, diabetic group and irbesartan treatment group. Semi-quantitative RT-PCR and immunohistochemistry were used to detect the expression of fractalkine mRNA and protein in renal cortex. Results Serum levels of glycosylation end products - peptide, urea nitrogen (BUN), 24h urine and fractalkine mRNA and protein expression in diabetic cortex were significantly higher than those in the control group. Serum levels of BUN and 24hUPro , While the expression of fractalkine mRNA and protein in renal cortex was significantly lower than that in diabetic group. Conclusion Irbesartan may exert its renal protective effect by inhibiting the expression of fractalkine in renal cortex.